Get the Stockscreener App
4.36
0.93%
0.04
After Hours:
4.39
0.03
+0.69%
Immuneering Corp stock is traded at $4.36, with a volume of 459.55K.
It is up +0.93% in the last 24 hours and down -8.40% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$4.32
Open:
$4.38
24h Volume:
459.55K
Relative Volume:
0.31
Market Cap:
$282.08M
Revenue:
$500
Net Income/Loss:
$-54.44M
P/E Ratio:
-3.7399
EPS:
-1.1658
Net Cash Flow:
$-49.91M
1W Performance:
+1.63%
1M Performance:
-8.40%
6M Performance:
-16.63%
1Y Performance:
+7.39%
1-Day Range:
$4.33
$4.51
1-Week Range:
$4.27
$4.51
52-Week Range:
$2.90
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.36 | 279.49M | 500 | -54.44M | -49.91M | -1.1658 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Initiated | Leerink Partners | Outperform |
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
Immuneering Corp (IMRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
IMRX|Immuneering Corp|Price:4.320|Chg%:-0.070 - TradingKey
TradingKey - TradingKey
Stock Ratings | Morgan Stanley raised its target price for Intel (INTC) to $75; Maxim Group initiated coverage on Rein Therapeutics (RNTX) with a target price of $4, representing a potential gain of 373.93%. - Sahm
Immuneering Corporation (IMRX) Stock Price, News, Quote & History - Yahoo! Finance Canada
Immuneering reports preclinical data on atebimetinib in journal - Investing.com
IMRX Maintains by Needham -- Price Target Raised to $18.00 - GuruFocus
Immuneering Corporation Announces Grants of Inducement Awards - The Manila Times
Form 4 Immuneering Corp For: 17 July By Investing.com - Investing.com Nigeria
IMRX News | IMMUNEERING CORPCLASS A (NASDAQ:IMRX) - ChartMill
Immuneering (IMRX) awards CFO Andrew Gengos 650,000 stock options - Stock Titan
Immuneering Corporation Announces Inducement Equity Grants to New CFO and Employee - Quiver Quantitative
Immuneering’s New CFO Gets 650,000-Share Option With $4.78 Exercise Price - Stock Titan
Immuneering Corp (IMRX) CFO discloses 225,000 Class A shares - Stock Titan
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Cantor Fitzgerald initiates Immuneering stock with overweight rating - Investing.com
If You Invested $1,000 in Immuneering Corp (IMRX) - Stock Titan
IMRXImmuneering Corp Latest SEC Filings - Finviz
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth - Sahm
IMRX Q1 2026 Earnings: Narrower Loss Drives Optimism for Clinical PipelineEarnings Revision Report - dars.gov.et
Immuneering Corp. Class A Actuals & Estimates (NASDAQ:IMRX) - TradingView
IMRX Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 Immuneering Corp For: 24 June By Investing.com - Investing.com Nigeria
Immuneering CEO Zeskind buys $10,948 in stock - Investing.com UK
Immuneering CEO Zeskind buys $10,948 in stock By Investing.com - Investing.com India
Immuneering CEO buys 2,400 shares in open market | IMRX Insider Trading - Stock Titan
Immuneering Corp (IMRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Immuneering Corp (IMRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Immuneering Corp (IMRX) Institutional Confidence - TradingKey
Immuneering Corp (IMRX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Immuneering Corp (IMRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Immuneering Corp (IMRX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Immuneering Corp (IMRX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Immuneering Corp (IMRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Insider Buying: Brett Hall Acquires Additional Shares of Immunee - GuruFocus
Immuneering (NASDAQ: IMRX) CSO purchases 6,035 shares in open-market trade - Stock Titan
New CFO Andrew Gengos joins Immuneering (NASDAQ: IMRX) with equity grant - Stock Titan
Immuneering names Andrew Gengos as CFO - MSN
Immuneering names Andrew Gengos as chief financial officer - Investing.com
Immuneering Appoints Andrew Gengos as Chief Financial Officer - The Manila Times
Immuneering names Andrew Gengos as chief financial officer By Investing.com - Investing.com Canada
IMRX begins dosing in phase III pancreatic cancer study, stock up - MSN
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up - Yahoo Finance
Immuneering Corporation Files Form 8-K with SEC Detailing Company Information as of June 11, 2026 - Minichart
Immuneering doses first patient in phase 3 pancreatic cancer trial - Investing.com
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer - The Manila Times
Immuneering Corporation Initiates Pivotal Phase 3 MAPKeeper 301 Trial to Evaluate Atebimetinib in Combination with mGnP for Metastatic Pancreatic Cancer - Quiver Quantitative
Pancreatic cancer trial tests atebimetinib combo, results expected mid-2028 - Stock Titan
Uprising in pancreatic space more than Revolution - BioWorld News
Oppenheimer reiterates Immuneering stock rating on pipeline progress - Investing.com
Mizuho reiterates Immuneering stock rating after trial data update - Investing.com
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
0.83%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):